HHS Approves Pharma’s Drug Discount Rebate Models for Pilot (1)

The US Department of Health and Human Services approved select drugmakers’ proposals to discount medicines through rebates under a federal drug program, greenlighting plans that will change how medicines reach low-income and uninsured patients.

Drugmakers including Bristol Myers Squibb Co., Novo Nordisk A/S, and AstraZeneca PLC received the rubber stamp for their models to participate in a rebate pilot under the federal 340B Drug Pricing Program, according to an updated webpage from the HHS’s Health Resources and Services Administration.

Manufacturers under the 340B program currently provide up-front drug discounts to covered entities, such as qualifying safety-net hospitals, clinics, ...